Literature DB >> 32615564

Similarities, Differences, and Potential Synergies in the Mechanism of Action of Albumin Dialysis Using the MARS Albumin Dialysis Device and the CytoSorb Hemoperfusion Device in the Treatment of Liver Failure.

Adrian Dominik1,2, Jan Stange3,4.   

Abstract

INTRODUCTION: Liver failure is characterized by compromised hepatic detoxification, protein synthesis, and metabolic derangements leading to an accumulation of a broad spectrum of water-soluble and lipophilic toxins as well as immune system mediators. Exploring complex detoxification mechanisms to therapeutically target those components, this article will focus on similarities, differences, and potential synergies in the mechanism of albumin dialysis and hemoperfusion.
METHODS: An in vitro two-compartment model for the comparison of liver support techniques was used to compare MARS albumin dialysis modified with novel charcoal adsorbents to CytoSorb hemoperfusion with added hemodialysis for effects on marker molecule removal.
RESULTS: MARS and CytoSorb performed similar in the removal of water-soluble toxins. Ammonia removal was increased using CytoSorb. CytoSorb lead to a statistically significant reduction of albumin-bound toxins, total bilirubin and subfractions. Bile acid removal was comparable. MARS demonstrated no removal of cytokines interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-α), whereas CytoSorb allowed for near complete removal. Notably, CytoSorb displayed 50% of lipophilic substance and cytokine removal during the first hour of treatment.
CONCLUSION: Compared to MARS, CytoSorb hemoperfusion leads to an initially fast removal of cytokines, TNF-α and IL-6, as well as reduction of albumin-bound toxins such as indirect bilirubin and bile acids in our model. The initial removal is also associated with removal of albumin.
© 2020 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Albumin dialysis; CytoSorb®; Extracorporeal liver support; Hemoperfusion; MARS®

Year:  2020        PMID: 32615564     DOI: 10.1159/000508810

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  6 in total

Review 1.  Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: a systematic review and network meta-analysis.

Authors:  Klementina Ocskay; Anna Kanjo; Noémi Gede; Zsolt Szakács; Gabriella Pár; Bálint Erőss; Jan Stange; Steffen Mitzner; Péter Hegyi; Zsolt Molnár
Journal:  Ann Intensive Care       Date:  2021-01-18       Impact factor: 6.925

2.  Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study.

Authors:  Christina Scharf; Uwe Liebchen; Michael Paal; Andrea Becker-Pennrich; Michael Irlbeck; Michael Zoller; Ines Schroeder
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

3.  Technical Note: Novel Use of CytoSorb™ Haemadsorption to Provide Wound Healing Support in Case of Severe Burn Trauma via Reduction of Hyperbilirubinaemia.

Authors:  Katarzyna Rachunek; Maja Krause; Johannes Tobias Thiel; Jonas Kolbenschlag; Adrien Daigeler; Andreas Bury
Journal:  Front Surg       Date:  2021-12-17

4.  Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP)-a single center, open-label, three-arm, randomized, controlled intervention trial.

Authors:  Asieb Sekandarzad; Enya Weber; Eric Peter Prager; Erika Graf; Dominik Bettinger; Tobias Wengenmayer; Alexander Supady
Journal:  Trials       Date:  2022-03-18       Impact factor: 2.279

5.  Cytokine filter application in COVID-19 patients; island of hope for crash and burn patients or future solution for all septic acute respiratory distress syndrome (ARDS) patients.

Authors:  Ali Ghodsizad
Journal:  J Card Surg       Date:  2021-07-18       Impact factor: 1.778

6.  Kinetics of Bilirubin and Ammonia Elimination during Hemadsorption Therapy in Secondary Sclerosing Cholangitis Following ECMO Therapy and Severe COVID-19.

Authors:  Désirée Tampe; Peter Korsten; Sebastian C B Bremer; Martin S Winkler; Björn Tampe
Journal:  Biomedicines       Date:  2021-12-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.